Trial Profile
Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2012
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Ramipril
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms ALISEI
- 17 Jun 2011 New trial record